Year-end Sale % OFF 
Abstract
Viruses in the Flaviviridae family are important human and animal pathogens that impose serious threats to global public health. This family of viruses includes emerging and re-emerging viruses, most of which are transmitted by infected mosquito or tick bites. Currently, there is no protective vaccine or effective antiviral treatment against the majority of these viruses, and due to their growing spread, several strategies have been employed to manufacture prophylactic vaccines against these infectious agents including virus-like particle (VLP) subunit vaccines. VLPs are genomeless viral particles that resemble authentic viruses and contain critical repetitive conformational structures on their surface that can trigger the induction of both humoral and cellular responses, making them safe and ideal vaccine candidates against these viruses. In this review, we focus on the potential of the VLP platform in the current vaccine development against the medically important viruses in the Flaviviridae family.
Highlights
The Flaviviridae family of positive sense, single-stranded enveloped RNA viruses are some of the most widely distributed and important human and animal viral pathogens that cause significant morbidity and mortality worldwide yearly
Multiple dosing and periodic boosting are commonly required for non-infectious vaccines, which can raise the cost of vaccination as well as the challenge for immunizing remote populations [88]
It should be noted that the type of expression system used has important influences on the performance and production of the virus-like particle (VLP) vaccine, and should be carefully chosen considering the specific virus of interest
Summary
The Flaviviridae family of positive sense, single-stranded enveloped RNA viruses are some of the most widely distributed and important human and animal viral pathogens that cause significant morbidity and mortality worldwide yearly. The VLP vaccine platform is based on the simple expression of self-assembling viral structural proteins (prME or CprME for most members of the Flaviviridae family, and C, E1 and E2 for HCV) [7,8] to produce non-replicative VLPs lacking a viral genome but retaining the morphology and antigenicity of live infectious virions, rendering VLP vaccines highly safe but immunogenic [9] Their unique feature of presenting viral antigens in highly native surface geometry organization and conformation allow VLP vaccines to efficiently elicit strong B-cell activation for high titre neutralizing antibody production, as well as activation of cellular immune response, inducing more potent protective immune responses as compared to subunit vaccines based on single proteins [9,10]. We focus on the potential of the VLP vaccine platform in the current vaccine development against the different species of Flaviviridae viruses named above
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
